Protecting Pharmaceutical Innovation in Brazil Despite the Lack of a Patent Linkage SystemLitigation remains a viable strategy for ensuring market exclusivity despite limitations from the Bolar Exemption.
Other Barks & Bites for Friday, March 28: House Passes Interagency R&D Bills; CAFC Affirms Induced Infringement Finding Against Mylan; and Several Drug Patent Bills Introduced into CongressMylan's proposed ANDA label is found to likely induce infringement of Janssen's patent on antipsychotic treatments, according to the Federal Circuit.
Protecting Pharmaceutical Innovation in Brazil Despite the Lack of a Patent Linkage SystemLitigation remains a viable strategy for ensuring market exclusivity despite limitations from the Bolar Exemption.
Other Barks & Bites for Friday, March 28: House Passes Interagency R&D Bills; CAFC Affirms Induced Infringement Finding Against Mylan; and Several Drug Patent Bills Introduced into CongressMylan's proposed ANDA label is found to likely induce infringement of Janssen's patent on antipsychotic treatments, according to the Federal Circuit.